Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%
Amgen ‘looks forward’ to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.
You may also be interested in...
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.
Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.
Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside Medicare's reimbursement bundle for end-stage renal disease.